Skip to main content
NASDAQ:MNKD

MannKind Competitors

$4.31
+0.28 (+6.95 %)
(As of 05/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.08
$4.39
50-Day Range
$3.59
$4.83
52-Week Range
$1.19
$6.25
Volume3.82 million shs
Average Volume5.29 million shs
Market Capitalization$1.07 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.28

Competitors

MannKind (NASDAQ:MNKD) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying MNKD stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to MannKind, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

MannKind (NASDAQ:MNKD) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Earnings & Valuation

This table compares MannKind and Amgen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MannKind$63.04 million17.03$-51,900,000.00($0.27)-15.96
Amgen$23.36 billion6.18$7.84 billion$14.8216.96

Amgen has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for MannKind and Amgen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MannKind01402.80
Amgen291402.48

MannKind presently has a consensus price target of $6.30, suggesting a potential upside of 46.17%. Amgen has a consensus price target of $255.6190, suggesting a potential upside of 1.69%. Given MannKind's stronger consensus rating and higher probable upside, research analysts plainly believe MannKind is more favorable than Amgen.

Profitability

This table compares MannKind and Amgen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MannKind-71.92%N/A-46.80%
Amgen29.42%95.55%15.52%

Volatility & Risk

MannKind has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Insider and Institutional Ownership

29.6% of MannKind shares are owned by institutional investors. Comparatively, 75.2% of Amgen shares are owned by institutional investors. 1.1% of MannKind shares are owned by insiders. Comparatively, 0.4% of Amgen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Amgen beats MannKind on 9 of the 14 factors compared between the two stocks.

MannKind (NASDAQ:MNKD) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Earnings & Valuation

This table compares MannKind and Gilead Sciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MannKind$63.04 million17.03$-51,900,000.00($0.27)-15.96
Gilead Sciences$22.45 billion3.83$5.39 billion$6.1411.16

Gilead Sciences has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for MannKind and Gilead Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MannKind01402.80
Gilead Sciences091202.57

MannKind presently has a consensus price target of $6.30, suggesting a potential upside of 46.17%. Gilead Sciences has a consensus price target of $100.5909, suggesting a potential upside of 46.78%. Given Gilead Sciences' higher probable upside, analysts plainly believe Gilead Sciences is more favorable than MannKind.

Profitability

This table compares MannKind and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MannKind-71.92%N/A-46.80%
Gilead Sciences5.48%37.77%12.76%

Volatility & Risk

MannKind has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500.

Insider and Institutional Ownership

29.6% of MannKind shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 1.1% of MannKind shares are owned by insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Gilead Sciences beats MannKind on 10 of the 14 factors compared between the two stocks.

MannKind (NASDAQ:MNKD) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Earnings & Valuation

This table compares MannKind and Vertex Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MannKind$63.04 million17.03$-51,900,000.00($0.27)-15.96
Vertex Pharmaceuticals$4.16 billion13.50$1.18 billion$4.2950.60

Vertex Pharmaceuticals has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for MannKind and Vertex Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MannKind01402.80
Vertex Pharmaceuticals041612.86

MannKind presently has a consensus price target of $6.30, suggesting a potential upside of 46.17%. Vertex Pharmaceuticals has a consensus price target of $293.4737, suggesting a potential upside of 35.19%. Given MannKind's higher probable upside, research analysts plainly believe MannKind is more favorable than Vertex Pharmaceuticals.

Profitability

This table compares MannKind and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MannKind-71.92%N/A-46.80%
Vertex Pharmaceuticals38.51%28.55%20.68%

Volatility & Risk

MannKind has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.

Insider and Institutional Ownership

29.6% of MannKind shares are owned by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. 1.1% of MannKind shares are owned by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Vertex Pharmaceuticals beats MannKind on 11 of the 15 factors compared between the two stocks.

MannKind (NASDAQ:MNKD) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Earnings & Valuation

This table compares MannKind and Regeneron Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MannKind$63.04 million17.03$-51,900,000.00($0.27)-15.96
Regeneron Pharmaceuticals$7.86 billion7.04$2.12 billion$21.4724.06

Regeneron Pharmaceuticals has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for MannKind and Regeneron Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MannKind01402.80
Regeneron Pharmaceuticals051402.74

MannKind presently has a consensus price target of $6.30, suggesting a potential upside of 46.17%. Regeneron Pharmaceuticals has a consensus price target of $656.3810, suggesting a potential upside of 27.05%. Given MannKind's stronger consensus rating and higher probable upside, research analysts plainly believe MannKind is more favorable than Regeneron Pharmaceuticals.

Profitability

This table compares MannKind and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MannKind-71.92%N/A-46.80%
Regeneron Pharmaceuticals38.28%28.97%20.11%

Volatility & Risk

MannKind has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500.

Insider and Institutional Ownership

29.6% of MannKind shares are owned by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. 1.1% of MannKind shares are owned by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Regeneron Pharmaceuticals beats MannKind on 10 of the 14 factors compared between the two stocks.

MannKind (NASDAQ:MNKD) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Earnings & Valuation

This table compares MannKind and Biogen's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MannKind$63.04 million17.03$-51,900,000.00($0.27)-15.96
Biogen$14.38 billion2.93$5.89 billion$33.578.35

Biogen has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for MannKind and Biogen, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MannKind01402.80
Biogen4141202.27

MannKind presently has a consensus price target of $6.30, suggesting a potential upside of 46.17%. Biogen has a consensus price target of $305.5714, suggesting a potential upside of 9.05%. Given MannKind's stronger consensus rating and higher probable upside, research analysts plainly believe MannKind is more favorable than Biogen.

Profitability

This table compares MannKind and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MannKind-71.92%N/A-46.80%
Biogen35.63%51.00%23.54%

Volatility & Risk

MannKind has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.

Insider and Institutional Ownership

29.6% of MannKind shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 1.1% of MannKind shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Biogen beats MannKind on 9 of the 14 factors compared between the two stocks.

MannKind (NASDAQ:MNKD) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Earnings & Valuation

This table compares MannKind and Alexion Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MannKind$63.04 million17.03$-51,900,000.00($0.27)-15.96
Alexion Pharmaceuticals$4.99 billion7.68$2.40 billion$9.7417.81

Alexion Pharmaceuticals has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

29.6% of MannKind shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 1.1% of MannKind shares are owned by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares MannKind and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MannKind-71.92%N/A-46.80%
Alexion Pharmaceuticals16.32%23.16%14.76%

Volatility & Risk

MannKind has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for MannKind and Alexion Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MannKind01402.80
Alexion Pharmaceuticals015402.21

MannKind presently has a consensus price target of $6.30, suggesting a potential upside of 46.17%. Alexion Pharmaceuticals has a consensus price target of $159.3158, suggesting a potential downside of 8.17%. Given MannKind's stronger consensus rating and higher probable upside, research analysts plainly believe MannKind is more favorable than Alexion Pharmaceuticals.

Summary

Alexion Pharmaceuticals beats MannKind on 9 of the 13 factors compared between the two stocks.


MannKind Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$251.38+0.4%$144.43 billion$23.36 billion20.27Insider Selling
Gilead Sciences logo
GILD
Gilead Sciences
2.8$68.53+0.6%$85.95 billion$22.45 billion70.65
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.0$217.09+1.3%$56.20 billion$4.16 billion27.41
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$516.62+0.1%$55.35 billion$7.86 billion18.88Analyst Report
Biogen logo
BIIB
Biogen
1.5$280.21+0.5%$42.19 billion$14.38 billion9.28
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$173.49+0.1%$38.34 billion$4.99 billion40.54
Seagen logo
SGEN
Seagen
1.5$147.50+1.9%$26.77 billion$916.71 million58.07Insider Selling
Incyte logo
INCY
Incyte
1.6$82.62+0.7%$18.17 billion$2.16 billion-52.62Analyst Report
Exact Sciences logo
EXAS
Exact Sciences
2.0$96.74+3.2%$16.60 billion$876.29 million-43.77Analyst Report
Analyst Revision
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$135.70+2.0%$15.95 billion$219.75 million-17.33
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$76.93+1.8%$14.06 billion$1.70 billion17.60Insider Selling
Novavax logo
NVAX
Novavax
1.8$131.69+8.1%$9.76 billion$18.66 million-25.23Earnings Announcement
Analyst Report
Analyst Revision
Gap Down
Repligen logo
RGEN
Repligen
1.9$171.96+1.3%$9.44 billion$270.24 million209.71Analyst Report
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$94.60+2.8%$8.94 billion$788.10 million101.72Analyst Report
Unusual Options Activity
Gap Down
United Therapeutics logo
UTHR
United Therapeutics
1.7$197.87+2.1%$8.86 billion$1.45 billion18.72Analyst Report
Exelixis logo
EXEL
Exelixis
1.9$25.56+0.4%$8.01 billion$967.78 million53.25Insider Selling
Gap Down
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$43.03+2.9%$6.13 billion$195.99 million268.94Earnings Announcement
Analyst Downgrade
Insider Selling
Analyst Revision
News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$38.24+2.3%$5.39 billion$1.12 billion79.67Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$61.46+1.6%$3.73 billion$806.43 million-8.71Analyst Report
Alkermes logo
ALKS
Alkermes
1.2$22.26+0.1%$3.57 billion$1.17 billion-48.39Insider Selling
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$62.00+5.6%$3.32 billion$1.11 billion19.94Analyst Report
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.4$9.49+1.3%$2.52 billion$182.24 million-8.25Earnings Announcement
Analyst Revision
News Coverage
OPKO Health logo
OPK
OPKO Health
1.9$3.70+7.8%$2.48 billion$901.90 million-20.55Insider Buying
Gap Down
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.3$12.84+6.9%$2.28 billion$48.83 million-16.89Gap Down
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.5$134.70+2.3%$2.23 billionN/A-12.17Analyst Revision
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$129.52+4.4%$2.16 billion$120.28 million-130.83Gap Down
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$27.38+6.3%$2.11 billion$638.60 million-10.53Gap Down
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$11.68+1.7%$1.88 billion$428.41 million16.93
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$10.85+4.1%$1.56 billion$102.43 million-18.08Analyst Revision
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$6.75+5.2%$1.35 billion$82.27 million-16.46Earnings Announcement
Analyst Revision
Innoviva logo
INVA
Innoviva
1.1$12.87+0.9%$1.30 billion$261.02 million6.57
Curis logo
CRIS
Curis
1.3$13.57+3.7%$1.24 billion$10 million-16.55Earnings Announcement
Analyst Report
Unusual Options Activity
Analyst Revision
News Coverage
Gap Down
Codexis logo
CDXS
Codexis
1.5$18.29+3.8%$1.18 billion$68.46 million-52.26Gap Down
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$27.09+7.7%$1.07 billion$3.57 million-12.15Gap Down
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$18.65+1.3%$1.04 billion$227.19 million51.81Analyst Report
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$7.80+6.0%$893.79 million$35.22 million-5.69Analyst Downgrade
Gap Down
ChemoCentryx logo
CCXI
ChemoCentryx
1.7$10.44+4.5%$728.19 million$36.13 million-15.58Analyst Report
Gap Down
Agenus logo
AGEN
Agenus
1.6$3.23+6.2%$718.48 million$150.05 million-2.96Analyst Upgrade
Gap Down
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.17+4.4%$683.21 million$150,000.00-4.53Analyst Report
Gap Down
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.3$18.79+2.4%$682.60 millionN/A0.00High Trading Volume
Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.71+2.4%$631.31 million$59.29 million-24.73Gap Down
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.33+3.0%$625.20 million$322.07 million-4.12Analyst Revision
News Coverage
Gap Down
Clovis Oncology logo
CLVS
Clovis Oncology
1.2$5.87+4.3%$613.80 million$143.01 million-1.12Analyst Report
Gap Down
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$18.15+5.1%$601.89 million$252 million-1.86Analyst Report
Gap Down
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.48+12.1%$541.88 million$109.33 million-2.56Earnings Announcement
News Coverage
Gap Down
Verastem logo
VSTM
Verastem
1.5$2.94+4.8%$505.44 million$17.46 million-2.09Earnings Announcement
Analyst Report
News Coverage
Gap Down
Geron logo
GERN
Geron
1.4$1.43+6.3%$455.55 million$460,000.00-4.09Earnings Announcement
Analyst Upgrade
Analyst Revision
Gap Down
Molecular Templates logo
MTEM
Molecular Templates
2.0$7.86+6.1%$440.85 million$22.27 million-3.85Earnings Announcement
News Coverage
Fortress Biotech logo
FBIO
Fortress Biotech
1.6$3.68+1.9%$357.90 million$36.63 million-4.33Upcoming Earnings
XOMA logo
XOMA
XOMA
1.5$29.92+2.1%$337.20 million$18.37 million-26.95Analyst Revision
Gap Down
This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.